Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer.
Urothelial bladder cancer is the ninth most common cancer. Despite surgical and chemotherapeutic treatment the prognosis is still poor once bladder cancer progresses to a muscle-invasive state. Discovery of new diagnostic markers and pathophysiologic effectors might help to contribute to novel diagn...
Main Authors: | Christian Niedworok, Katharina Röck, Inga Kretschmer, Till Freudenberger, Nadine Nagy, Tibor Szarvas, Frank Vom Dorp, Henning Reis, Herbert Rübben, Jens W Fischer |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3819308?pdf=render |
Similar Items
-
The impact of the receptor of hyaluronan-mediated motility (RHAMM) on human urothelial transitional cell cancer of the bladder.
by: Christian Niedworok, et al.
Published: (2013-01-01) -
Functional role of the small leucine-rich repeat proteoglycan (SLRP) biglycan in gastric cancer
by: Liliana Manuela Santos Ferreira
Published: (2021) -
The Extracellular Small Leucine-Rich Proteoglycan Biglycan Is a Key Player in Gastric Cancer Aggressiveness
by: Filipe Pinto, et al.
Published: (2021-03-01) -
Altered expression of small leucine-rich proteoglycans (Decorin, Biglycan and Lumican): Plausible diagnostic marker in urothelial carcinoma of bladder
by: Sandeep Appunni, et al.
Published: (2017-04-01) -
The small leucine-rich proteoglycan, biglycan, is highly expressed in adipose tissue of Psammomys obesus and is associated with obesity and type 2 diabetes
by: Bolton K, et al.
Published: (2012-04-01)